Cell and Gene Therapy Manufacturing Market - Global Industry Analysis

Cell and Gene Therapy Manufacturing Market - By Therapy Type (Cell Therapy Manufacturing and Gene Therapy Manufacturing), By Scale (R&D and Commercial), By Workflow (Vector Production and Cell Banking), And By Region- Global Industry Perspective, Comprehensive Analysis, and Forecast, 2021 – 2028

Published Date: 20-Jul-2021 Category: Biotechnology Report Format : PDF Pages: 150 Report Code: ZMR-6498 Status : Published

The global Cell and Gene Therapy Manufacturing market accrued earnings worth approximately 12.59 (USD Billion) in 2020 and is predicted to gain revenue of about 23.21(USD Billion) by 2028, is set to record a CAGR of nearly 20.2% over the period from 2021 to 2028.

Description

The global Cell and Gene Therapy Manufacturing market accrued earnings worth approximately 12.59 (USD Billion) in 2020 and is predicted to gain revenue of about 23.21(USD Billion) by 2028, is set to record a CAGR of nearly 20.2% over the period from 2021 to 2028. The report offers assessment and analysis of the Cell and Gene Therapy Manufacturing market on a global and regional level. The study offers a comprehensive assessment of the market competition, constraints, revenue estimates, opportunities, evolving trends, and industry-validated data. The report provides historical data from 2018 to 2020 along with a forecast from 2021 to 2028 based on revenue (USD Billion).

Report Scope :

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Cell and Gene Therapy Manufacturing Market: Synopsis

Cell and gene therapies are niche ones and hence giant pharma firms are adding new products to existing product line, thereby enhancing manufacturing capacities. Apart from this, mammoth pharma companies such as Thermo Fisher, Novartis, Catalent, and Roche are investing millions of dollars to improve manufacturing capacity of products used in cell & gene treatments, thereby enlarging scope of cell and gene therapy manufacturing business. Precisely, in cell therapy, cells are modified out of patient body and then again injected into the body of patient, thereby making them function as live medicine. In gene therapy, gene is either deactivated, substituted, or introduced into human cells which are inside human body or taken outside human body. Gene therapy is utilized for treating various kinds of chronic disorders in living beings. Apparently, gene as well as cell treatments are designed for halting disease proliferation as well as reversing growth of disease.

Furthermore, giant firms are investing massively in cell & gene treatment research activities and expanding their base through acquisitions. Citing an instance, in 2019, Novartis purchased CELLforCure – a largest French-based contract development & manufacturing organizations manufacturing cell & gene treatments – from LFB. Furthermore, acquisition encompassed cell & gene manufacturing unit situated in outskirts of Paris. The strategic move was aimed at developing effective CAR-T cell treatments as well as expanding research activities & base of Novartis in cell & gene therapy domain in France. Reportedly, firms such as Novartis has taken many steps for reinforcing & expanding its cell & gene manufacturing activities through entering into licensing, collaboration, and purchase agreement with Cellular Biomedicine Group for producing as well as supplying Kymriah – first CAR-T cell treatment approved by U.S. FDA -  to China. Apart from this, Novartis formed alliance with Fraunhofer institute in Germany for facilitating cell & gene manufacturing for clinical tests & post approval cell & gene manufacturing. It had also entered into contract cell & gene manufacturing agreement with Japan. All these aforementioned aspects will assist cell and gene therapy manufacturing market explore new paths of growth in upcoming years.

Cell and Gene Therapy Manufacturing Market: Growth Dynamics

Evolution of new therapies has brought a paradigm shift in biopharma sector and will revolutionize life-threatening & rare disease treatment, thereby steering growth of cell and gene therapy manufacturing market. In addition to this, rapid spread of COVID-19 virus across the globe has favorably influenced expansion of cell and gene therapy manufacturing market size. Regulations supporting use of cell & gene treatments for various diseases will augment scope of cell and gene therapy manufacturing market growth in forthcoming years. Decentralized manufacturing of cell and gene therapies is likely to bring a drastic transformation in cell & gene therapy manufacturing approach, thereby driving market trends. Mergers & acquisitions have also shaped growth of cell and gene therapy manufacturing industry in recent years. Citing an instance, in May 2019, Catalent Inc. - a leading provider of drugs, consumer health products, and biologics- acquired Paragon BioServices Incorporation- a major viral vector developer & provider of manufacturing solutions for gene treatments- for nearly USD 1.2 billion. Reportedly, in May 2019, Thermo Fisher Scientific Inc. acquired Brammer Bio- a major viral vector producer for cell and gene treatments- for nearly USD 1.7 billion in cash. In April 2019, Hitachi Chemical- a Japanese firm manufacturing chemicals- acquired apceth Biopharma GmbH- a Germany based CDMO for gene & cell treatments- for nearly USD 86.5 million with a view for expanding its business in new cell & gene therapy contract development & manufacturing solutions domain. Additionally, the strategic move is aimed at development of regenerative drug business in the U.S., Japan, and Europe, thereby not only expanding its regional base but to accrue huge profits by entering in niche business of cell & gene manufacturing & launching differentiated &  innovative products. Earlier in 2017, Hitachi had purchased PCT, LLC – a U.S. headquartered contract producer of regenerative drugs- and then had commenced its manufacturing & contract development operations for producing regenerative drugs in April 2018 at its new unit in Yokohama, Japan.

Apart from this, new entrants are also likely to shape growth of cell and gene therapy manufacturing market in foreseeable future. For instance, small firm such as bluebird bio- a Massachusettes-based gene & cell therapy firm- had set up its cell and gene therapy manufacturing establishment in Durham in March 2019 with an objective for producing lentiviral vector to investigate gene & cell treatments. Moreover, in 2018, Abeona Therapeutics – a Texas-based biopharma firm- established a GMP manufacturing unit in Cleveland in the U.S. with an aim to carry out research on gene & cell treatments. During same year, Mustang Bio- a New York based biopharma organization, inaugurated a CAR T cell treatment manufacturing base at Worcester in Massachusetts in the U.S.

Furthermore, gene and cell based treatments possess huge potential for offering new modes of treatment for several severe ailments and this will pave a way for humungous growth of cell and gene therapy manufacturing market in coming decade. With new insights in disease biology & evolution of new cellular mechanisms has resulted in rapid development & production of regenerative & immunotherapeutic medicines, thereby aiding growth of cell and gene therapy manufacturing industry over the assessment period.

Global Cell and Gene Therapy Manufacturing Market

Regional Landscape

North America To Contribute Majorly Towards Market Size By 2028

The growth of cell and gene therapy manufacturing market in North America over assessment period is owing to surge in proportion of clinical studies in countries such as the U.S. In addition to this, increase in funding of research activities pertaining to cell & gene treatments will further boost scope of market in the sub-continent over the following years. Apart from this, large-scale presence of firms into cell & gene therapy business in the sub-continent will drive the business landscape in region over forecast timeline. New product development, mergers & acquisitions, partnerships, agreements, strategic alliances & collaborations between firm, and licensing of drugs & medicine patenting or trade copyrights have favorably influenced regional market growth.

Competitive Landscape

Key participants profiled in report and influencing market proceeds include Lonza AG, Thermo Fisher Scientific, Merck KGaA, Catalent Inc., Roche Diagnostics Limited, Takara Bio Incorporation, Boehringer Ingelheim, Wuxi Advanced Therapeutics, Novartis AG, Hitachi Chemical Company Limited, Bluebird Bio Inc., and Cellular Therapeutics.

The global Cell and Gene Therapy Manufacturing Market is segmented as follows:

By Workflow

  • Vector Production
  • Cell Banking

By Therapy Type

  • Cell Therapy Manufacturing
  • Gene Therapy Manufacturing

By Scale

  • R&D
  • Commercial

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Type
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Cell and Gene Therapy Manufacturing Market, 2018–2028(USD Billion)
    • 2.2. Cell and Gene Therapy Manufacturing Market: Snapshot
  • Chapter 3. Global Cell and Gene Therapy Manufacturing Market– Workflow Analysis
    • 3.1. Cell and Gene Therapy Manufacturing Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Emergence of new drug treatment has brought a revulution in biopharma sector and is expected to bring swift transformation in treatment modes of life-threatening & rare disease, thereby translating into cell and gene therapy manufacturing market expansion in forthcoming years.
      • 3.2.2. Rapid spread of COVID-19 virus across the globe has resulted in massive elevation of cell and gene therapy manufacturing market size.
    • 3.3. Porter’s Five Forces Analysis
    • 3.4. Market Attractiveness Analysis
      • 3.4.1. Market attractiveness analysis By Workflow
      • 3.4.2. Market attractiveness analysis By Therapy Type
      • 3.4.3. Market attractiveness analysis By Scale
  • Chapter 4. Global Cell and Gene Therapy Manufacturing Market– Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Cell and Gene Therapy Manufacturing Market: company market share, 2019
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Product launches
      • 4.2.3. Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Cell and Gene Therapy Manufacturing Market– Workflow Analysis
    • 5.1. Global Cell and Gene Therapy Manufacturing Market overview: By Workflow
      • 5.1.1. Global Cell and Gene Therapy Manufacturing Market share, By Workflow , 2020 and 2028
    • 5.2. Vector Production
      • 5.2.1. Global Cell and Gene Therapy Manufacturing Market by Vector Production, 2018–2028(USD Billion)
    • 5.3. Cell Banking
      • 5.3.1. Global Cell and Gene Therapy Manufacturing Market by Cell Banking, 2018–2028(USD Billion)
  • Chapter 6. Global Cell and Gene Therapy Manufacturing Market– Therapy Type Analysis
    • 6.1. Global Cell and Gene Therapy Manufacturing Market overview: By Therapy Type
      • 6.1.1. Global Cell and Gene Therapy Manufacturing Market share, By Therapy Type , 2020 and 2028
    • 6.2. Cell Therapy Manufacturing
      • 6.2.1. Global Cell and Gene Therapy Manufacturing Market by Cell Therapy Manufacturing, 2018–2028(USD Billion)
    • 6.3. Gene Therapy Manufacturing
      • 6.3.1. Global Cell and Gene Therapy Manufacturing Market by Gene Therapy Manufacturing, 2018–2028(USD Billion)
  • Chapter 7. Global Cell and Gene Therapy Manufacturing Market– Scale Analysis
    • 7.1. Global Cell and Gene Therapy Manufacturing Market overview: By Scale
      • 7.1.1. Global Cell and Gene Therapy Manufacturing Market share, By Scale, 2020 and 2028
    • 7.2. R&D
      • 7.2.1. Global Cell and Gene Therapy Manufacturing Market by R&D, 2018–2028(USD Billion)
    • 7.3. Commercial
      • 7.3.1. Global Cell and Gene Therapy Manufacturing Market by Commercial, 2018–2028(USD Billion)
  • Chapter 8. Company Profiles
    • 8.1. Lonza AG
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Product Portfolio
      • 8.1.4. Business Strategy
      • 8.1.5. Recent Developments
    • 8.2. Thermo Fisher Scientific
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Product Portfolio
      • 8.2.4. Business Strategy
      • 8.2.5. Recent Developments
    • 8.3. Merck KGaA
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Product Portfolio
      • 8.3.4. Business Strategy
      • 8.3.5. Recent Development
    • 8.4. Catalent Inc.
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Product Portfolio
      • 8.4.4. Business Strategy
      • 8.4.5. Recent Development
    • 8.5. Roche Diagnostics Limited
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Product Portfolio
      • 8.5.4. Business Strategy
      • 8.5.5. Recent Development
    • 8.6. Takara Bio Incorporation
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Product Portfolio
      • 8.6.4. Business Strategy
      • 8.6.5. Recent Development
    • 8.7. Boehringer Ingelheim
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Product Portfolio
      • 8.7.4. Business Strategy
      • 8.7.5. Recent Development
    • 8.8. Wuxi Advanced Therapeutics
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. Product Portfolio
      • 8.8.4. Business Strategy
      • 8.8.5. Recent Development
    • 8.9. Novartis AG
      • 8.9.1. Overview
      • 8.9.2. Financials
      • 8.9.3. Product Portfolio
      • 8.9.4. Business Strategy
      • 8.9.5. Recent Development
    • 8.10. Hitachi Chemical Company Limited
      • 8.10.1. Overview
      • 8.10.2. Financials
      • 8.10.3. Product Portfolio
      • 8.10.4. Business Strategy
      • 8.10.5. Recent Development
    • 8.11. Bluebird Bio Inc.
      • 8.11.1. Overview
      • 8.11.2. Financials
      • 8.11.3. Product Portfolio
      • 8.11.4. Business Strategy
      • 8.11.5. Recent Development
    • 8.12. Cellular Therapeutics
      • 8.12.1. Overview
      • 8.12.2. Financials
      • 8.12.3. Product Portfolio
      • 8.12.4. Business Strategy
      • 8.12.5. Recent Development

List of Figures

1. Market research Type
2. Market research methodology
3. Global Cell and Gene Therapy Manufacturing Market, 2018–2028(USD Billion)
4. Porter’s Five Forces Analysis
5. Global Cell and Gene Therapy Manufacturing Marketattractiveness, By Workflow
6. Global Cell and Gene Therapy Manufacturing Marketattractiveness, By Therapy Type 
7. Global Cell and Gene Therapy Manufacturing Marketattractiveness, By Scale
8. Global Cell and Gene Therapy Manufacturing Marketshare by Workflow ,2020 and 2028 (USD Billion)
9. Global Cell and Gene Therapy Manufacturing Marketby Vector Production, 2018–2028(USD Billion)
10. Global Cell and Gene Therapy Manufacturing Marketby Cell Banking, 2018–2028(USD Billion)
11. Global Cell and Gene Therapy Manufacturing Marketshare by Therapy Type  ,2020 and 2028 (USD Billion)
12. Global Cell and Gene Therapy Manufacturing Marketby Cell Therapy Manufacturing, 2018–2028(USD Billion)
13. Global Cell and Gene Therapy Manufacturing Marketby Gene Therapy Manufacturing, 2018–2028(USD Billion)
14. Global Cell and Gene Therapy Manufacturing Marketshare by Scale ,2020 and 2028 (USD Billion)
15. Global Cell and Gene Therapy Manufacturing Marketby R&D, 2018–2028(USD Billion)
16. Global Cell and Gene Therapy Manufacturing Marketby Commercial, 2018–2028(USD Billion)
17. Global Cell and Gene Therapy Manufacturing Marketshare, by Region, 2020 and 2028
18. North America Cell and Gene Therapy Manufacturing Market, 2018–2028(USD Billion)
19. Europe Cell and Gene Therapy Manufacturing Market, 2018–2028(USD Billion)
20. Asia Pacific Cell and Gene Therapy Manufacturing Market, 2018–2028(USD Billion)
21. Latin America Cell and Gene Therapy Manufacturing Market, 2018–2028(USD Billion)
22. The Middle East and Africa Cell and Gene Therapy Manufacturing Market, 2018–2028(USD Billion)
 


List of Tables

1. Global Cell and Gene Therapy Manufacturing Market: snapshot
2. Drivers of the Cell and Gene Therapy Manufacturing Market: impact analysis
3. North America Cell and Gene Therapy Manufacturing Market revenue, By Workflow  ,2018–2028(USD Billion)
4. North America Cell and Gene Therapy Manufacturing Market revenue, By Therapy Type   ,2018–2028(USD Billion)
5. North America Cell and Gene Therapy Manufacturing Market revenue, By Scale  ,2018–2028(USD Billion)
6. The U.S. Cell and Gene Therapy Manufacturing Market revenue, By Workflow  ,2018–2028(USD Billion)
7. The U.S. Cell and Gene Therapy Manufacturing Market revenue, By Therapy Type   ,2018–2028(USD Billion)
8. The U.S. Cell and Gene Therapy Manufacturing Market revenue, By Scale  ,2018–2028(USD Billion)
9. Rest of North America Cell and Gene Therapy Manufacturing Market revenue, By Workflow  ,2018–2028(USD Billion)
10. Rest of North America Cell and Gene Therapy Manufacturing Market revenue, By Therapy Type   ,2018–2028(USD Billion)
11. Rest of North America Cell and Gene Therapy Manufacturing Market revenue, By Scale  ,2018–2028(USD Billion)
12. Europe Cell and Gene Therapy Manufacturing Market revenue, By Workflow  ,2018–2028(USD Billion)
13. Europe Cell and Gene Therapy Manufacturing Market revenue, By Therapy Type   ,2018–2028(USD Billion)
14. Europe Cell and Gene Therapy Manufacturing Market revenue, By Scale  ,2018–2028(USD Billion)
15. UK Cell and Gene Therapy Manufacturing Market revenue, By Workflow  ,2018–2028(USD Billion)
16. UK Cell and Gene Therapy Manufacturing Market revenue, By Therapy Type   ,2018–2028(USD Billion)
17. UK Cell and Gene Therapy Manufacturing Market revenue, By Scale  ,2018–2028(USD Billion)
18. France Cell and Gene Therapy Manufacturing Market revenue, By Workflow  ,2018–2028(USD Billion)
19. France Cell and Gene Therapy Manufacturing Market revenue, By Therapy Type   ,2018–2028(USD Billion)
20. France Cell and Gene Therapy Manufacturing Market revenue, By Scale  ,2018–2028(USD Billion)
21. Germany Cell and Gene Therapy Manufacturing Market revenue, By Workflow  ,2018–2028(USD Billion)
22. Germany Cell and Gene Therapy Manufacturing Market revenue, By Therapy Type   ,2018–2028(USD Billion)
23. Germany Cell and Gene Therapy Manufacturing Market revenue, By Scale  ,2018–2028(USD Billion)
24. Rest of Europe Cell and Gene Therapy Manufacturing Market revenue, By Workflow  ,2018–2028(USD Billion)
25. Rest of Europe Cell and Gene Therapy Manufacturing Market revenue, By Therapy Type   ,2018–2028(USD Billion)
26. Rest of Europe Cell and Gene Therapy Manufacturing Market revenue, By Scale  ,2018–2028(USD Billion)
27. Asia Pacific Cell and Gene Therapy Manufacturing Market revenue, By Workflow  ,2018–2028(USD Billion)
28. Asia Pacific Cell and Gene Therapy Manufacturing Market revenue, By Therapy Type   ,2018–2028(USD Billion)
29. Asia Pacific Cell and Gene Therapy Manufacturing Market revenue, By Scale  ,2018–2028(USD Billion)
30. China Cell and Gene Therapy Manufacturing Market revenue, By Workflow  ,2018–2028(USD Billion)
31. China Cell and Gene Therapy Manufacturing Market revenue, By Therapy Type   ,2018–2028(USD Billion)
32. China Cell and Gene Therapy Manufacturing Market revenue, By Scale  ,2018–2028(USD Billion)
33. Japan Cell and Gene Therapy Manufacturing Market revenue, By Workflow  ,2018–2028(USD Billion)
34. Japan Cell and Gene Therapy Manufacturing Market revenue, By Therapy Type   ,2018–2028(USD Billion)
35. Japan Cell and Gene Therapy Manufacturing Market revenue, By Scale  ,2018–2028(USD Billion)
36. India Cell and Gene Therapy Manufacturing Market revenue, By Workflow  ,2018–2028(USD Billion)
37. India Cell and Gene Therapy Manufacturing Market revenue, By Therapy Type   ,2018–2028(USD Billion)
38. India Cell and Gene Therapy Manufacturing Market revenue, By Scale  ,2018–2028(USD Billion)
39. Rest of Asia Pacific Cell and Gene Therapy Manufacturing Market revenue, By Workflow  ,2018–2028(USD Billion)
40. Rest of Asia Pacific Cell and Gene Therapy Manufacturing Market revenue, By Therapy Type   ,2018–2028(USD Billion)
41. Rest of Asia Pacific Cell and Gene Therapy Manufacturing Market revenue, By Scale  ,2018–2028(USD Billion)
42. Latin America Cell and Gene Therapy Manufacturing Market revenue, By Workflow  ,2018–2028(USD Billion)
43. Latin America Cell and Gene Therapy Manufacturing Market revenue, By Therapy Type   ,2018–2028(USD Billion)
44. Latin America Cell and Gene Therapy Manufacturing Market revenue, By Scale  ,2018–2028(USD Billion)
45. Brazil Cell and Gene Therapy Manufacturing Market revenue, By Workflow  ,2018–2028(USD Billion)
46. Brazil Cell and Gene Therapy Manufacturing Market revenue, By Therapy Type   ,2018–2028(USD Billion)
47. Brazil Cell and Gene Therapy Manufacturing Market revenue, By Scale  ,2018–2028(USD Billion)
48. Rest of Latin America Cell and Gene Therapy Manufacturing Market revenue, By Workflow  ,2018–2028(USD Billion)
49. Rest of Latin America Cell and Gene Therapy Manufacturing Market revenue, By Therapy Type   ,2018–2028(USD Billion)
50. Rest of Latin  America Cell and Gene Therapy Manufacturing Market revenue, By Scale  ,2018–2028(USD Billion)
51. The Middle East and Africa Cell and Gene Therapy Manufacturing Market revenue, By Workflow  ,2018–2028(USD Billion)
52. The Middle East and Africa Cell and Gene Therapy Manufacturing Market revenue, By Therapy Type   ,2018–2028(USD Billion)
53. The Middle East and Africa Cell and Gene Therapy Manufacturing Market revenue, By Scale  ,2018–2028(USD Billion)
54. Saudi Arabia Cell and Gene Therapy Manufacturing Market revenue, By Workflow  ,2018–2028(USD Billion)
55. Saudi Arabia Cell and Gene Therapy Manufacturing Market revenue, By Therapy Type   ,2018–2028(USD Billion)
56. Saudi Arabia Cell and Gene Therapy Manufacturing Market revenue, By Scale  ,2018–2028(USD Billion)
57. South Africa Cell and Gene Therapy Manufacturing Market revenue, By Workflow  ,2018–2028(USD Billion)
58. South Africa Cell and Gene Therapy Manufacturing Market revenue, By Therapy Type   ,2018–2028(USD Billion)
59. South Africa Cell and Gene Therapy Manufacturing Market revenue, By Scale  ,2018–2028(USD Billion)
60. Rest of the Middle East & Africa Cell and Gene Therapy Manufacturing Market revenue, By Workflow  ,2018–2028(USD Billion)
61. Rest of the Middle East & Africa Cell and Gene Therapy Manufacturing Market revenue, By Therapy Type   ,2018–2028(USD Billion)
62. Rest of the Middle East & Africa Cell and Gene Therapy Manufacturing Market revenue, By Scale  ,2018–2028(USD Billion)
 
 

Methodology

Choose License Type

Request the coronavirus impact analysis across industries and markets

FrequentlyAsked Questions

Evolution of new therapies has brought a paradigm shift in biopharma sector and will revolutionize life-threatening & rare disease treatment, thereby steering growth of cell and gene therapy manufacturing market. In addition to this, rapid spread of COVID-19 virus across the globe has favorably influenced expansion of cell and gene therapy manufacturing market size. Regulations supporting use of cell & gene treatments for various diseases will augment scope of cell and gene therapy manufacturing market growth in forthcoming years. Decentralized manufacturing of cell and gene therapies is likely to bring a drastic transformation in cell & gene therapy manufacturing approach, thereby driving market trends. Mergers & acquisitions have also shaped growth of cell and gene therapy manufacturing industry in recent years. Citing an instance, in May 2019, Catalent Inc. - a leading provider of drugs, consumer health products, and biologics- acquired Paragon BioServices Incorporation- a major viral vector developer & provider of manufacturing solutions for gene treatments- for nearly USD 1.2 billion. Reportedly, in May 2019, Thermo Fisher Scientific Inc. acquired Brammer Bio- a major viral vector producer for cell and gene treatments- for nearly USD 1.7 billion in cash. In April 2019, Hitachi Chemical- a Japanese firm manufacturing chemicals- acquired apceth Biopharma GmbH- a Germany based CDMO for gene & cell treatments- for nearly USD 86.5 million with a view for expanding its business in new cell & gene therapy contract development & manufacturing solutions domain. Additionally, the strategic move is aimed at development of regenerative drug business in the U.S., Japan, and Europe, thereby not only expanding its regional base but to accrue huge profits by entering in niche business of cell & gene manufacturing & launching differentiated &  innovative products. Earlier in 2017, Hitachi had purchased PCT, LLC – a U.S. headquartered contract producer of regenerative drugs- and then had commenced its manufacturing & contract development operations for producing regenerative drugs in April 2018 at its new unit in Yokohama, Japan.

According to Zion market research report, the global Cell and Gene Therapy Manufacturing market accrued earnings worth approximately 12.59 (USD Billion) in 2020 and is predicted to gain revenue of about 23.21(USD Billion) by 2028, is set to record a CAGR of nearly 20.2% over the period from 2021 to 2028.

North America will contribute lucratively towards the global market size over the estimated timeline. The regional market surge is due to surge in proportion of clinical experiments in countries such as the U.S. Additionally, increase in funding of research activities pertaining to cell & gene treatments will further boost scope of market in the sub-continent during forecasting years. Apart from this, large-scale presence of firms into cell & gene therapy business in the sub-continent will steer industry landscape in region over forecast timeline. Product innovation, mergers & acquisitions, partnerships, agreements, strategic alliances & collaborations between firm, and licensing of drugs & medicine patenting or trade copyrights have favorably leveraged regional market growth.

The key market participants leveraging business growth and contributing majorly towards market profitability & industry size include Lonza AG, Thermo Fisher Scientific, Merck KGaA, Catalent Inc., Roche Diagnostics Limited, Takara Bio Incorporation, Boehringer Ingelheim, Wuxi Advanced Therapeutics, Novartis AG, Hitachi Chemical Company Limited, Bluebird Bio Inc., and Cellular Therapeutics.

HappyClients

Office Address

Corporate Office

Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed